Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt | ($38.8M) | ($72.6M) | ($208.1M) | ($450.2M) | ($430.4M) | ($281.4M) | ($233.1M) | ($146.4M) | ($226.2M) | ($350.5M) | ($976.5M) | ($1,332.4M) | ($792.6M) | ($1,674.5M) | ($1,052.9M) | ($956.2M) | ($1,339.9M) | ($249.9M) | $420.1M | $243.2M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month Net Debt is ($1,470.1M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Debt growth was 34.0%. The average annual Net Debt growth rates for Alnylam Pharmaceuticals, Inc. have been 7.3% over the past three years, 5.7% over the past five years.
Over the last year, Alnylam Pharmaceuticals, Inc.'s Net Debt growth was 34.0%, which is higher than industry growth of (0.1%). It indicates that Alnylam Pharmaceuticals, Inc.'s Net Debt growth is Bad.